This article focuses on the emerging role of matrix metalloproteinase-12 (MMP-12) in
ischaemic stroke (IS). MMP-12 expression in the brain increases dramatically in animal …

Background Acute ischemic stroke (AIS) is a common cerebrovascular event associated with
high incidence, disability, and poor prognosis. Studies have shown that various cell types …

Ischemic stroke is a leading cause of disability and mortality worldwide. The only approved
treatment for ischemic stroke is thrombolytic therapy with tissue plasminogen activator (tPA) …

Backgroud Exercise training is the main strategy for stroke rehabilitation, and it has shown
that shifting microglia toward M2 phenotype is beneficial for the recovery of neurological …

Ischaemic stroke characterises impulsive cerebral-region hypoxia due to deep intracerebral
arteriole blockage, often accompanied by permanent cerebral infarction and cognitive …

Abstract N6-Methyladenosine (m6A) is a neuronal-enriched, reversible post-transcriptional
modification that regulates RNA metabolism. The m6A-modified RNAs recruit various m6A …

Previous studies have demonstrated that endogenous tissue-type plasminogen activator
(tPA) is upregulated in the brain after an acute ischemic stroke (AIS). While mixed results …

Purpose To determine the effect of the sodium-glucose cotransporter protein 2 (SGLT2)
inhibition on ischemic stroke (IS) and investigate the circulating proteins that mediate the …

Background Accumulating evidence suggests that matrix metalloproteinase (MMP) 12 plays
a detrimental role in cerebro-cardiovascular diseases, including ischemic stroke (IS) …

Acute Ischemic Stroke (AIS) is a major public health burden, involving several diagnostics,
therapeutic and prognostic concerns. Endovascular treatment (EVT), using stent-retriever …